The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | WU-KONG1: sunvozertinib in NSCLC with EGFR exon 20 insertion mutations
James Chih-Hsin Yang, MD, MPH, National Taiwan University, Taipei, Taiwan, discusses findings from the Phase II WU-KONG1 study (NCT03974022) of sunvozertinib in pre-treated patients with EGFR exon 20 insertion-mutated (exon20ins) non-small cell lung cancer (NSCLC). Objective response rates (ORR) were higher than in previous studies that assessed amivantamab or mobocertinib. Safety findings indicate manageable treatment-related adverse events. The results support sunvozertinib as a promising treatment for this patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Amgen; AstraZeneca; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Dizal Pharma; Gilead Sciences; Lilly; MSD; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; Roche; Roche/Genentech; Sanofi/Regeneron; Taiho Pharmaceutical; Takeda; Takeda
Consulting or Advisory Role – Abbvie; Amgen; Amgen; AstraZeneca; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; Gilead Sciences; GlaxoSmithKline; Hansoh; Incyte; Janssen Oncology; Lilly; Merck KGaA; MSD Oncology; MSD Oncology; Novartis; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Takeda; Takeda; Yuhan
Research Funding – AstraZeneca
Travel, Accommodations, Expenses – Pfizer
